Personalized Outreach for Rheumatic Diseases

(POET-Rheum Trial)

CM
Overseen ByChu Ming (Alec) Yu, MD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of British Columbia
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores whether financial incentives or personalized outreach can help people with rheumatic diseases (conditions causing pain and inflammation in joints) attend medical appointments more regularly. The study compares three groups to determine the most effective method: offering a small cash honorarium, providing both honoraria and outreach services, or neither. People with inflammatory arthritis connected to specific Vancouver health centers and able to attend in-person visits may be suitable candidates. Participants must fill out surveys and attend monthly check-ups if they begin certain medications.

As an unphased trial, this study provides a unique opportunity to contribute to research that could enhance appointment attendance strategies for patients with rheumatic diseases.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It mainly focuses on improving appointment attendance through honoraria and outreach services.

What prior data suggests that these outreach methods are safe?

In a previous study, researchers explored how small financial rewards (honoraria) and outreach services can improve patient health. Reports have shown that financial incentives can positively influence health habits, with no direct evidence of safety issues from these non-medical approaches.

Since this study does not involve a new drug or medical treatment, typical safety concerns like side effects do not apply. Honoraria provide patients with a small financial reward for attending appointments, while outreach services offer personalized health reminders. These methods are generally considered safe because they do not involve medication or medical procedures.

For any concerns or questions about how these strategies might affect you, discussing them with the study team or your healthcare provider is advisable.12345

Why are researchers excited about this trial?

Researchers are excited about this trial because it explores new ways to help patients with rheumatic diseases stay engaged with their healthcare. Unlike standard treatments that focus on medication, this trial is testing the impact of personalized outreach and financial incentives, known as honoraria, on patient follow-up attendance. By combining these innovative approaches, the trial aims to find out if they can improve how often patients attend their appointments, which is crucial for managing chronic conditions like inflammatory arthritis. This could lead to better patient outcomes by ensuring more consistent care and monitoring.

What evidence suggests that this trial's treatments could be effective for improving attendance rates at a rheumatology clinic?

Research shows that financial rewards, such as honoraria, can increase patient participation in healthcare. Studies have found that patients are more likely to attend appointments when they receive money. In this trial, one group will receive only honoraria. Another group will receive both honoraria and personalized outreach services, which can help reduce health disparities, especially in rheumatology. These services provide specific support and information, encouraging regular follow-up care. Combining honoraria with outreach services may further improve appointment attendance by addressing both financial and informational challenges.14678

Who Is on the Research Team?

BR

Brent R Ohata, MD

Principal Investigator

University of British Columbia

Are You a Good Fit for This Trial?

This trial is for individuals with various rheumatic diseases like Rheumatoid Arthritis and Psoriatic Arthritis, who visit an inner city clinic in Vancouver. Participants should be willing to attend regular appointments and complete surveys. Details on specific inclusion or exclusion criteria are not provided.

Inclusion Criteria

I am 18 years or older and can consent to participate.
Be attached to one of the Vancouver Coastal Health Community Health Centres for primary care
Be willing to attend in-person appointments at Pender Community Health Centre
See 2 more

Exclusion Criteria

Have no reasonably reliable method of contact (phone, email, social media, etc.)
I do not have severe cognitive or untreated psychiatric conditions.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Randomization and Baseline Assessment

Participants are randomized to receive either honoraria alone or honoraria with outreach services. Baseline surveys on health and rheumatic disease understanding are completed.

1 week
1 visit (in-person)

Treatment and Monitoring

Participants receive monthly in-person assessments and bloodwork monitoring. Outreach services include biweekly phone calls, text messages, or home visits.

6 months
6 visits (in-person), biweekly outreach (phone/text/home visits)

Follow-up

Participants are monitored for safety and effectiveness after treatment. Surveys and semi-structured interviews are conducted at 3-month and 6-month intervals.

6 months
2 visits (in-person)

What Are the Treatments Tested in This Trial?

Interventions

  • Honoraria
  • Outreach
Trial Overview The study tests if financial incentives ($20 honoraria) and personalized outreach services increase appointment attendance at a rheumatology clinic. Patients will either receive just the honoraria or both the honoraria and outreach services, compared to standard care.
How Is the Trial Designed?
3Treatment groups
Experimental Treatment
Active Control
Group I: Honoraria and OutreachExperimental Treatment2 Interventions
Group II: Historical ControlActive Control1 Intervention
Group III: Honoraria OnlyActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of British Columbia

Lead Sponsor

Trials
1,506
Recruited
2,528,000+

Mary Pack Arthritis Center

Collaborator

Citations

Outcome measures in inflammatory rheumatic diseases - PMCInflammatory rheumatic diseases are generally multifaceted disorders and, therefore, measurement of multiple outcomes is relevant to most of these diseases.
a meta-epidemiological studyA trend was observed where trials selecting patients with higher baseline disease activity found a higher risk ratio of WDdtAEs and SAEs, but also a lower risk ...
Real world data in rheumatologyReal world data plays an important role in rheumatology, allowing us to gain deeper insights into disease progression and treatment outcomes, ...
Honoraria, Consulting Linked to Positive RA Trial ResultsThe researchers found a temporal increase in RA clinical trial author FOIs from 54.2% in 2002-03 and 52.7% in 2006-07 to 65.1% in 2010-11 (P = .
Economic and Humanistic Burden of Rheumatoid Arthritis ...Patients with RA are likely to have a two- to three-year reduction in life expectancy than the general population, primarily due to other ...
Risk of infection in patients with early inflammatory arthritisAn observational cohort study was used, including adults in England and Wales with new diagnoses of RA between 2018 and 2023. The main outcome was SI events, ...
Safety outcomes in patients with rheumatoid arthritis treated ...Data suggest that the risk of infections in patients with RA is further increased with the use of conventional synthetic (cs) disease-modifying ...
Infection outcomes in patients with rheumatoid arthritis ...Data from this international, observational study showed similar hospitalized infection risk for abatacept versus csDMARDs or other b/tsDMARDs.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security